Agreements

* On April 3, 2014, Merck Serono has announced an exclusive license agreement with Auxogyn, a Californian company dedicated to advancing women’s reproductive health, for Auxogyn’s proprietary Early Embryo Viability Assessment (Eeva®) Test. The Eeva Test results deliver objective information that may assist clinicians in improving IVF (in vitro fertilization) patient outcomes. Under the terms of the agreement, Merck Serono will obtain exclusive rights to commercialize the Eeva Test® in Europe and Canada, with the option to extend to selected countries and regions. The license agreement builds on a successful relationship between the companies that was started in 2010 when Merck Serono initially invested in Auxogyn through a Series A Preferred Stock financing made by Merck Serono’s corporate venture capital fund, MS Ventures. In 2012, Merck Serono and Auxogyn announced a strategic partnership on the Eeva Test. Auxogyn received the CE mark for the Eeva System in 2012, and it is currently available for use in certain countries in the European Union and Canada. In the United States, where Auxogyn retains commercialization rights, Auxogyn has filed a submission with the FDA for the clearance of the Eeva System, and this application is currently under review by the FDA.